Nezha Benabdallah's Avatar

Nezha Benabdallah

@nsbenab.bsky.social

Group leader at the University of Edinburgh. Chromatin, Gene Regulation & Sarcoma https://www.benabdallah-lab.com/

1,142 Followers  |  427 Following  |  17 Posts  |  Joined: 21.12.2023  |  2.0846

Latest posts by nsbenab.bsky.social on Bluesky

Preview
Opinion | Iโ€™m the Prime Minister of Spain. This Is Why the West Needs Migrants.

'The regularization effort underway in Spain actually began as a citizen-led initiative endorsed by more than 900 nongovernmental organizations, including the Catholic Church, and it has the support of business associations and trade unions alike.'

www.nytimes.com/2026/02/04/o...

06.02.2026 15:07 โ€” ๐Ÿ‘ 5    ๐Ÿ” 6    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
EZS European Zebrafish Society The European Zebrafish Society was formed as a successor of "EuFishBioMed e.V." to foster zebrafish research, providing a platform for researchers and a framewokr for grant funding for young researche...

Congratulations to @ezsociety.bsky.social Christiane Nรผsslein-Volhard Award winner Liz Patton for her pioneering work with zebrafish models in melanoma research, outstanding scientific excellence, unwavering dedication to community service & shaping of learned societies ๐Ÿ‘‰https://edin.ac/4r1an7d

05.02.2026 12:52 โ€” ๐Ÿ‘ 7    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

RESEARCH PAPER: SOX2 phosphorylation during mitosis limits genomic damage
By Williams et al., and Steven Pollard
โžก๏ธ https://genesdev.cshlp.org/content/40/3-4/185.full

Edinburgh University
#sox2 #chromatin #neural #mitosis #stemcells #phosphorylation

04.02.2026 19:00 โ€” ๐Ÿ‘ 6    ๐Ÿ” 3    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

This is for you โ€“ and a great opportunity โ€“ if you are establishing a group in Croatia, Czechia, Estonia, Hungary, Lithuania, Luxembourg, Poland, Portugal and Tรผrkiye...

04.02.2026 08:42 โ€” ๐Ÿ‘ 5    ๐Ÿ” 8    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
DOT1L provides transcriptional memory through PRC1.1 antagonism - Nature Cell Biology Neville, Ferguson et al. show that non-canonical Polycomb repressive complex 1.1-mediated gene silencing is antagonized by DOT1L and is required for the therapeutic efficacy of Menin and DOT1L inhibit...

www.nature.com/articles/s41...

happy i could be a part of this paper from the Gilan lab out now. Along with many other things, it provides strong evidence of chromatin memory for gene activation, and suggests that DOT1L is the missing link balancing the fast and slow arms of the MLL/Polycomb axis

03.02.2026 21:29 โ€” ๐Ÿ‘ 22    ๐Ÿ” 7    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Ad for a postdoc position in centromere biology with colorful chromosomes and centromeres made out of FIMO.

Ad for a postdoc position in centromere biology with colorful chromosomes and centromeres made out of FIMO.

๐Ÿงช My lab has an opening for a postdoc position soon! Please share/get in touch!

03.02.2026 13:59 โ€” ๐Ÿ‘ 13    ๐Ÿ” 17    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

Today in @natgenet.nature.com, we report a saturation genome editing study that systematically dissects the degron of ฮฒ-Catenin, which contains 5 of the 25 most frequently mutated regions of the human cancer genome, and >70 recurrent missense mutations.

rdcu.be/e1Tvk

02.02.2026 16:10 โ€” ๐Ÿ‘ 15    ๐Ÿ” 5    ๐Ÿ’ฌ 3    ๐Ÿ“Œ 0

Congratulations Pradeep!

02.02.2026 20:07 โ€” ๐Ÿ‘ 1    ๐Ÿ” 0    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Video thumbnail

Check out our new findings showing BRD4's role in preventing the premature activation of developmental transcription factors via #Polycomb, providing new mechanistic insights into the pathogenesis of neurodevelopmental disorder #CdLS #NDDs, #chromatinopathies www.biorxiv.org/content/10.6...

02.02.2026 07:19 โ€” ๐Ÿ‘ 35    ๐Ÿ” 14    ๐Ÿ’ฌ 7    ๐Ÿ“Œ 1
An example of a voter suppression ad on Facebook. This ad was part of a Russian election interference campaign.

An example of a voter suppression ad on Facebook. This ad was part of a Russian election interference campaign.

Exposure to voter suppression ads on Facebookโ€”which targeted non-White residents of battleground statesโ€”was associated with a 1.9% decrease in voter turnout in the 2016 election, representing approximately 4.7 million fewer votes nationwide. In PNAS: https://ow.ly/HJGf50Y7FPG

02.02.2026 20:01 โ€” ๐Ÿ‘ 10    ๐Ÿ” 7    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 1
Post image

๐Ÿ“ฃ I'm excited to share our latest preprint!

We adapt and characterise a neurosphere-based CNCC differentiation protocol, and demonstrate utility for quantitative phenotyping and craniofacial disease modelling! ๐Ÿงซ

Read about Array-CNCC here:
www.biorxiv.org/content/10.6...

@uoe-igc.bsky.social

28.01.2026 14:36 โ€” ๐Ÿ‘ 46    ๐Ÿ” 13    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 1
SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity Synovial sarcoma is driven by the SS18-SSX fusion oncoprotein, which has been assumed to promote tumorigenesis through its incorporation into the SWI/SNF chromatin remodeling complexes. Accordingly, therapeutic efforts have focused on targeting SS18-SSX containing SWI/SNF assemblies, yet these approaches have produced limited clinical benefit. Here, we demonstrate that SS18-SSX sustains oncogenic transcription independent of SWI/SNF activity. Despite efficient degradation and dismantling of SWI/SNF complexes, fusion occupancy at target loci and associated gene expression programs remain largely intact. Instead, we identify the acetyltransferase P300 as an essential co-factor supporting SS18-SSX chromatin binding and transcriptional activation. Targeting P300 displaces the fusion from chromatin, suppresses its transcriptional output, compromising synovial sarcoma viability. Notably, dual PROTAC mediated degradation of P300 and SWI/SNF produces strong synergistic effects, broadly disrupting SS18-SSX localization and function. These findings redefine the mechanistic basis of synovial sarcoma and reveal a mechanistically anchored therapeutic strategy for targeting its core oncogenic driver. ### Competing Interest Statement C.R.V. has been a consultant for Flare Therapeutics, Roivant Sciences and C4 Therapeutics; has served on the advisory boards of KSQ Therapeutics, Syros Pharmaceuticals and Treeline Biosciences; has received research funding from Boehringer Ingelheim and Treeline Biosciences; and owns stock in Treeline Biosciences. S.A.A. has been a consultant and/or shareholder for Neomorph, Imago Biosciences, Hyku Therapeutics, C4 Therapeutics, Accent Therapeutics and Nimbus Therapeutics; and has received research support from Janssen and Syndax. N.O.C. is a co-founder, shareholder and management consultant for PhenoTherapeutics Ltd; and a shareholder in Amplia Therapeutics Ltd All other authors declare no financial interests UKRI, EP/X039633/1 Worldwide Cancer Research, https://ror.org/031tfbz57, 21-0271 Science Foundation Ireland, https://ror.org/0271asj38, 18/SIRG/5573

Synovial sarcoma is driven almost exclusively by a single oncofusion โ€“ SS18-SSX

For years, the assumptions on disease mechanisms were simple:

โžก๏ธ SS18-SSX works by hijacking SWI/SNF chromatin remodeling activity

Our new study shows that assumption was wrong ๐Ÿงต๐Ÿ‘‡

www.biorxiv.org/content/10.6...

28.01.2026 09:54 โ€” ๐Ÿ‘ 24    ๐Ÿ” 10    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 2

I did not know she was on Bluesky, but this whole work was led by @afroditisotiriou.bsky.social, a truly talented scientist that will finish her PhD this year and has not started looking for postdoc positions yet...

28.01.2026 10:36 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity Synovial sarcoma is driven by the SS18-SSX fusion oncoprotein, which has been assumed to promote tumorigenesis through its incorporation into the SWI/SNF chromatin remodeling complexes. Accordingly, therapeutic efforts have focused on targeting SS18-SSX containing SWI/SNF assemblies, yet these approaches have produced limited clinical benefit. Here, we demonstrate that SS18-SSX sustains oncogenic transcription independent of SWI/SNF activity. Despite efficient degradation and dismantling of SWI/SNF complexes, fusion occupancy at target loci and associated gene expression programs remain largely intact. Instead, we identify the acetyltransferase P300 as an essential co-factor supporting SS18-SSX chromatin binding and transcriptional activation. Targeting P300 displaces the fusion from chromatin, suppresses its transcriptional output, compromising synovial sarcoma viability. Notably, dual PROTAC mediated degradation of P300 and SWI/SNF produces strong synergistic effects, broadly disrupting SS18-SSX localization and function. These findings redefine the mechanistic basis of synovial sarcoma and reveal a mechanistically anchored therapeutic strategy for targeting its core oncogenic driver. ### Competing Interest Statement C.R.V. has been a consultant for Flare Therapeutics, Roivant Sciences and C4 Therapeutics; has served on the advisory boards of KSQ Therapeutics, Syros Pharmaceuticals and Treeline Biosciences; has received research funding from Boehringer Ingelheim and Treeline Biosciences; and owns stock in Treeline Biosciences. S.A.A. has been a consultant and/or shareholder for Neomorph, Imago Biosciences, Hyku Therapeutics, C4 Therapeutics, Accent Therapeutics and Nimbus Therapeutics; and has received research support from Janssen and Syndax. N.O.C. is a co-founder, shareholder and management consultant for PhenoTherapeutics Ltd; and a shareholder in Amplia Therapeutics Ltd All other authors declare no financial interests UKRI, EP/X039633/1 Worldwide Cancer Research, https://ror.org/031tfbz57, 21-0271 Science Foundation Ireland, https://ror.org/0271asj38, 18/SIRG/5573

Also very cool co-ordinated back-to-back with a sister preprint from colleagues (and office mate) @gerrybrien.bsky.social reporting the same finding ๐Ÿค
www.biorxiv.org/content/10.6...

28.01.2026 10:21 โ€” ๐Ÿ‘ 2    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

SS18::SSX activates Polycomb target genes without BAF โŒ
Instead, transcription relies on EP300 via the SS18 QPGY domain
www.biorxiv.org/content/10.6...
โžก๏ธ Coactivator targeting emerges as a new therapeutic strategy in synovial sarcoma ๐ŸŽฏ
Team work from @banitolab.bsky.social and @uoe-igc.bsky.social

28.01.2026 10:20 โ€” ๐Ÿ‘ 22    ๐Ÿ” 16    ๐Ÿ’ฌ 3    ๐Ÿ“Œ 0

Anyone know anything about Jennifer Harvey, who first isolated the virus containing HRAS (Harvey-Ras) at Mill Hill in 1967?

Prepping a lecture including the discovery of Ras oncogenes and wanted to add pics of the scientists involved.

The Internet has NOTHING

#sciencehistory #forgottenwomen

23.01.2026 10:17 โ€” ๐Ÿ‘ 11    ๐Ÿ” 10    ๐Ÿ’ฌ 9    ๐Ÿ“Œ 2

Very cool! Can't wait to see single-cell TimeVault ๐Ÿคฉ

23.01.2026 00:22 โ€” ๐Ÿ‘ 3    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
A genetically encoded device for transcriptome storage in mammalian cells Understanding how cells make decisions over time requires the ability to link past molecular states to future phenotypic outcomes. We present TimeVault, a genetically encoded system that records and s...

๐Ÿงฌ๐Ÿ”ฌ@science.org A genetically encoded device for #transcriptome storage in mammalian cells | Science www.science.org/doi/10.1126/... @broadinstitute.org

15.01.2026 20:30 โ€” ๐Ÿ‘ 55    ๐Ÿ” 25    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 3
Yes, this is where you would work (the round building, not the boat)

Yes, this is where you would work (the round building, not the boat)

We are looking for a postdoc to join our team! If you're interested in translating a cutting edge genomics technology (www.nature.com/articles/s41...) to real-life applications in hematology, this is for you. We offer a unique working environment ON THE BEACH: recruitment.crg.eu/content/jobs...

20.11.2025 09:36 โ€” ๐Ÿ‘ 17    ๐Ÿ” 16    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 3
Preview
EASTBIO - Dissecting CIC::DUX4 oncogenic circuitry through single-cell perturbation profiling and network inference at University of Edinburgh on FindAPhD.com PhD Project - EASTBIO - Dissecting CIC::DUX4 oncogenic circuitry through single-cell perturbation profiling and network inference at University of Edinburgh, listed on FindAPhD.com

We have an exciting PhD opportunity through the EASTBIO programme, co-supervised with Diego Oyarzรบn. This project combines synthetic and systems biology to uncover the gene-regulatory circuitry hijacked in a cancer model. Weโ€™re looking for candidates with a strong interest in functional genomics.

19.11.2025 13:15 โ€” ๐Ÿ‘ 6    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 1
Preview
Why we made Affinity free, and how weโ€™ll keep it that way Weโ€™ve made Affinity completely free, empowering professional designers with studio-grade creative software, supported by Canvaโ€™s sustainable ecosystem.

I'm a longtime fan of Affinity Designer as an affordable Illustrator-killer for figures, and... it's now free?! www.canva.com/newsroom/new...
Highly recommended if you're sick of paying Adobe $. Maybe Canva can buy NPG too and get rid of the OA fees.

18.11.2025 23:28 โ€” ๐Ÿ‘ 40    ๐Ÿ” 10    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 4
Job opportunity postodoctoral research fellow closing 18th November 2025

Job opportunity postodoctoral research fellow closing 18th November 2025

๐Ÿ“ฃJob Opportunity: Develop machine learning of cellular automata models with applications to in vitro developmental biology.
More info: edin.ac/49Mr7ZQ

12.11.2025 14:30 โ€” ๐Ÿ‘ 2    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Congratulations @nsbenab.bsky.social and fellow experts joining the Independent Scientific Advisory Panel! ๐Ÿ‘
@cmvm-edinburghuni.bsky.social

12.11.2025 15:16 โ€” ๐Ÿ‘ 1    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Beautiful (jaw-dropping ๐Ÿ˜‰) work from Hannah Longโ€™s group revealing how Neandertal enhancers influence facial morphology!

10.11.2025 11:42 โ€” ๐Ÿ‘ 7    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

I guess I need to apologize to the writers of Alien: Prometheus. it turns out scientists really do touch everything like that

08.11.2025 16:30 โ€” ๐Ÿ‘ 2665    ๐Ÿ” 796    ๐Ÿ’ฌ 35    ๐Ÿ“Œ 26
Post image

๐ŸฅThis Wednesday , in #FragileNucleosome seminar, we are excited to host @hannahlong.bsky.social and @jeffvierstra.bsky.social to tell us about amazing work they are doing!
๐Ÿ—“๏ธRegister here for upcoming session and the entire series:
us06web.zoom.us/webinar/regi...

03.11.2025 12:03 โ€” ๐Ÿ‘ 20    ๐Ÿ” 12    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Promoter-proximal gatekeepers restrict pleiotropic enhancer inputs to achieve tissue specificity Developmental enhancers are central regulatory elements that can activate multiple genes, yet how they selectively regulate one gene over its neighbours remains unclear. Using the Drosophila twist E3 ...

Ever wondered what drives enhancer-promoter specificity? Why would an enhancer activate one gene rather than another neighboring one?

Check our latest preprint, led by @mmasoura.bsky.social, to find out!
www.biorxiv.org/content/10.1...

16.10.2025 12:33 โ€” ๐Ÿ‘ 100    ๐Ÿ” 42    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 5
Preview
Enhancer-promoter compatibility is mediated by the promoter-proximal region Gene promoters induce transcription in response to distal enhancers. How enhancers specifically activate their target promoter while bypassing other promoters remains unclear. Here, we find that the p...

What is a promoter? And how does it work?

We very happy to share our latest work trying to understand enhancer-promoter compatibility.
I am very excited about the results of @blanka-majchrzycka.bsky.social, which changed the way I think about promoters

www.biorxiv.org/content/10.1...

16.10.2025 15:06 โ€” ๐Ÿ‘ 170    ๐Ÿ” 74    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 6
Post image

Programmable promoter editing for precise control of transgene expression - @mitcheme.bsky.social @mitdeptofbe.bsky.social go.nature.com/4h9wlR1

13.10.2025 19:11 โ€” ๐Ÿ‘ 21    ๐Ÿ” 5    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 0
Post image

๐Ÿฆ– Something HUGE just hatched.

Plasmidsaurus now offers RNA sequencing for gene expression analysis:
โ€ข As fast as 3 day turnaround
โ€ข $50/sample for academia, $80 for industry
โ€ข Up to ~10M unique transcript 3โ€™ end reads per sample
โ€ข Interactive results

Explore Plasmidsaurus RNA-Seq today.

15.10.2025 16:02 โ€” ๐Ÿ‘ 92    ๐Ÿ” 36    ๐Ÿ’ฌ 4    ๐Ÿ“Œ 7

@nsbenab is following 20 prominent accounts